test tube close up


Nasdaq Stockholm Small Cap: ABLI

Market CapSEK203m

Last Close SEK0.18

Abliva is a Swedish biotech with deep expertise in mitochondrial medicine. Its lead assets are KL1333, an NAD+/NADH modulator (IND approved) and NV354, a succinate prodrug (preclinical). Abliva plans to start a pivotal Phase II/III trial with KL1333 in selected PMDs later this year.

More Abliva content >

Investment summary

Abliva is focused on primary mitochondrial diseases (PMD). The core portfolio consists of KL1333 and NV354. KL1333 is a small molecule NAD+/NADH modulator used to restore intracellular energy balance. With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III FALCON trial with KL1333 and is expected to start screening patients in H222. Abliva is also progressing with its other core asset, NV354, as a systemic treatment for Leigh syndrome, with preparations ongoing for a Phase I start. In June Abliva completed a c SEK200m funding (SEK150m private placement and SEK50m rights issue), which is expected to provide the company with a 24-month cash runway through to mid-2024.

Y/E Dec
Revenue (SEKm)
EPS (fd) (öre)
P/E (x)
P/CF (x)
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021A 0.2 (117.9) (120.4) (34.44) N/A N/A
2022E 0.2 (128.2) (128.9) (17.67) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
Industry outlook

Abliva has a diversified portfolio, with all assets aimed at improving mitochondrial metabolism and function. We believe this puts Abliva among the very few experts in mitochondrial medicine.

Last updated on 04/10/2022
Content on Abliva
Abliva – IND approved by the FDA, preparing for Ph II/III
Healthcare | research Update | 13 January 2022
Abliva – KL1333 ready for pivotal Phase II/III trial
Healthcare | research Update | 27 May 2021
Abliva – New strategic investor on board and CMD
Healthcare | research Update | 26 June 2020
View more
Register to receive research on Abliva as it is published
Share price graph
Balance sheet
Forecast net cash (SEKm) 28.6
Forecast gearing ratio (%) N/A
Price performance
Actual (14.9) (33.4) (66.7)
Relative* (11.4) (32.2) (56.9)
52-week high/low SEK0.7/SEK0.2
*% relative to local index
Key management
David Laskow-Pooley Chairman
Ellen Donnelly CEO
Catharina Jz Johansson CFO
Eskil Elmér Chief Scientist Officer
Magnus Hansson Chief Medical Officer